Oct 27 (Reuters) - Alexion Pharmaceuticals Inc ALXN.O
* Alexion initiates simultaneous registration trials of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (ahus)
* Trials to evaluate alxn1210 administered every eight weeks in patients with PNH and AHUS; enrollment to begin in q4
* Plans to initiate a Phase 3 trial of ALXN1210 in pediatric patients with ahus in 2017
* Commenced dosing of a new formulation of alxn1210 administered subcutaneously in healthy volunteers in a phase i study Source text for Eikon: ID:nBwDK7Bba Further company coverage: ALXN.O